Greek scientist expresses high hopes for patients with advanced lung cancer due to a pioneering vaccine

A pioneering mRNA vaccine trial is offering new hope to individuals battling advanced non-small cell lung cancer. The Agios Savvas Hospital in Greece has become a global leader in the study, currently ranking second in patient recruitment worldwide. Led by director Alexandros Ardavanis, the Phase 3 trial targets patients who have stopped responding to traditional immunotherapy treatments. This therapeutic vaccine works by re-energizing the immune system to recognize and attack malignant cells more effectively. Twelve medical centers across Greece are participating in this international effort, which is expected to conclude by 2028. The initiative follows the certification of Agios Savvas as the country's first Comprehensive Cancer Center, expanding access to innovative medicines.